- Home
- GLTO vs MTNB Comparison
GLTO vs MTNB Comparison
Compare GLTO & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- MTNB
- Stock Information
- Founded
- GLTO 2011
- MTNB 2013
- Country
- GLTO Denmark
- MTNB United States
- Employees
- GLTO N/A
- MTNB N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- MTNB Health Care
- Exchange
- GLTO Nasdaq
- MTNB Nasdaq
- Market Cap
- GLTO 4.5M
- MTNB 5.2M
- IPO Year
- GLTO 2020
- MTNB N/A
- Fundamental
- Price
- GLTO $3.21
- MTNB $0.87
- Analyst Decision
- GLTO Buy
- MTNB Hold
- Analyst Count
- GLTO 1
- MTNB 1
- Target Price
- GLTO $10.00
- MTNB N/A
- AVG Volume (30 Days)
- GLTO 29.8K
- MTNB 46.9K
- Earning Date
- GLTO 08-11-2025
- MTNB 08-13-2025
- Dividend Yield
- GLTO N/A
- MTNB N/A
- EPS Growth
- GLTO N/A
- MTNB N/A
- EPS
- GLTO N/A
- MTNB N/A
- Revenue
- GLTO N/A
- MTNB N/A
- Revenue This Year
- GLTO N/A
- MTNB N/A
- Revenue Next Year
- GLTO N/A
- MTNB N/A
- P/E Ratio
- GLTO N/A
- MTNB N/A
- Revenue Growth
- GLTO N/A
- MTNB N/A
- 52 Week Low
- GLTO $2.01
- MTNB $0.47
- 52 Week High
- GLTO $15.13
- MTNB $8.50
- Technical
- Relative Strength Index (RSI)
- GLTO 38.87
- MTNB 42.07
- Support Level
- GLTO $3.10
- MTNB $0.82
- Resistance Level
- GLTO $3.65
- MTNB $1.04
- Average True Range (ATR)
- GLTO 0.31
- MTNB 0.05
- MACD
- GLTO -0.06
- MTNB -0.02
- Stochastic Oscillator
- GLTO 10.61
- MTNB 23.77
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.